A Community-Based Chronic Pain Self-Management Program in West Virginia
A Randomized Controlled Trial of a Community-Based Chronic Pain Self-Management Program in West Virginia
Chronic pain (CP) affects 1 in 3 US adults and costs up to $635 billion annually in medical costs and lost work productivity. Use of opioid medications for CP has risen in the US, and opioid overdose deaths have quadrupled, yet with no overall change in pain. Although one-third of US adults have CP, there is a lack of affordable, non-pharmacological, evidence-based, community-delivered interventions for people with CP.
One program, the Chronic Pain Self-Management Program (CPSMP), provides short-term improvements in pain but its long-term effects have not been evaluated. This study will examine the long-term effects of CPSMP in the medically underserved state of West Virginia (WV). The objectives of this community-engaged, randomized, wait-list controlled study are to: 1) determine the short- (26 weeks) and long-term (52 weeks) effectiveness of the 6-week CPSMP in adults with CP in WV; 2) evaluate the Reach (number of participants, completers), Effectiveness (outcomes), Adoption (number of sites, leaders, trainings), Implementation (fidelity), and Maintenance (satisfaction, continuation) of CPSMP using the RE-AIM Framework; and 3) disseminate the results to key stakeholders including evidence-based organizations, public health practitioners/researchers, and healthcare providers.
The study will enroll 240 participants in 24 workshops at 12 community-based sites in 2 counties in WV, Greenbrier (rural) and Wood (urban). Participants will attend free, 2.5-hour weekly sessions for 6 weeks. Self-reported, performance-based, and physiological data will be collected at baseline and 26, and 52 weeks after the start of the intervention. The primary outcomes are pain (severity, quality, interference, medication use), mental health (mood, anxiety, catastrophizing), function (self-efficacy, coping, health-related quality of life, sleep, fatigue, communication, physical activity), healthcare utilization, missed work days, and gait speed.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Chronic pain (CP) affects 1 in 3 US adults and costs up to $635 billion annually in medical costs and lost work productivity. The impact of CP is worse in people with both CP and comorbid chronic diseases such as arthritis, diabetes, and heart disease. Use of opioid medications for CP has risen in the US, and opioid overdose deaths have quadrupled, yet with no overall change in pain. Although one-third of US adults have CP, there is a lack of affordable, non-pharmacological, evidence-based, community-delivered interventions for people with CP. Thus, there is a vital need to rigorously test more interventions that can be brought to scale and widely disseminated in the US.
One program, the Chronic Pain Self-Management Program (CPSMP), provides short-term improvements in pain but its long-term effects have not been evaluated. This study will examine the long-term effects of CPSMP in the medically underserved state of West Virginia (WV). With one of the worst health profiles in the US, WV has the highest rates of arthritis, diabetes, heart disease, and drug overdose deaths, and therefore has a compelling need for the CPSMP. The objectives of this community-engaged, randomized, wait-list controlled study are to: 1) determine the short- (26 weeks) and long-term (52 weeks) effectiveness of the 6-week CPSMP in adults with CP in WV; 2) evaluate the Reach (number of participants, completers), Effectiveness (outcomes), Adoption (number of sites, leaders, trainings), Implementation (fidelity), and Maintenance (satisfaction, continuation) of CPSMP using the RE-AIM Framework; and 3) disseminate the results to key stakeholders including evidence-based organizations, public health practitioners/researchers, and healthcare providers.
The study will enroll 240 participants in 24 workshops at 12 community-based sites in 2 counties in WV, Greenbrier (rural) and Wood (urban). Participants will attend free, 2.5-hour weekly sessions for 6 weeks. Two trained leaders will facilitate group discussions on managing pain, emotions, depression, fatigue, and sleep; proper exercise, nutrition, and medication use; weight management; strategies for effective communication with healthcare professionals; evaluating treatments; and pacing/planning. Self-reported, performance-based, and physiological data will be collected at baseline and 26, and 52 weeks after the start of the intervention. The primary outcomes are pain (severity, quality, interference, medication use), mental health (mood, anxiety, catastrophizing), function (self-efficacy, coping, health-related quality of life, sleep, fatigue, communication, physical activity), healthcare utilization, missed work days, and gait speed.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
West Virginia
-
Lewisburg, West Virginia, Verenigde Staten, 24901
- West Virginia School of Osteopathic Medicine
-
Parkersburg, West Virginia, Verenigde Staten, 26101
- Mid-Ohio Valley Health Department
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Adults over age 18
- Have chronic pain (pain on most days or everyday) for the past 3 months or more
- Able to attend 1 CPSMP workshop a week over 6 weeks
- Able to attend 3-4 testing sessions for data collection (testing sessions are scheduled before the workshops begin and then six months, one year and, for those assigned to the control group, one and a half years after the start of the study)
Exclusion Criteria:
- Chronic pain caused by current cancer diagnosis or an open wound
- Lack reliable transportation
- Having surgery for the painful area in the next year
- Not community-dwelling (i.e., living in a nursing home, assisted living or personal care home, mental hospital, or correctional facility)
- Not willing to be randomized to either start CPSMP workshop now or in six months
- Participation in another self-management program (e.g., Diabetes Self-Management Program) in the past 12 months
- Unable to speak English
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ander
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: CPSMP Intervention
Participants randomly assigned to this arm will, following a baseline assessment, immediately begin attending a 6-week Chronic Pain Self-Management Program (CPSMP) workshop.
|
Stanford University's Chronic Pain Self-Management Program (CPSMP) was developed by Sandra LeFort in 1996 and based on Stanford's Arthritis Self-Management Program and the Chronic Disease Self-Management Program.
The 6-week community-delivered workshop consists of 2.5-hour weekly sessions for people with a primary or secondary diagnosis of Chronic Pain.
|
|
Actieve vergelijker: Wait-list Control Group
Participants assigned to this arm will wait six months after a baseline assessment and then attend the 6-week Chronic Pain Self-Management Program (CPSMP) workshop.
|
Stanford University's Chronic Pain Self-Management Program (CPSMP) was developed by Sandra LeFort in 1996 and based on Stanford's Arthritis Self-Management Program and the Chronic Disease Self-Management Program.
The 6-week community-delivered workshop consists of 2.5-hour weekly sessions for people with a primary or secondary diagnosis of Chronic Pain.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Pain severity
Tijdsspanne: Change between baseline and 52 weeks
|
Using Stanford's 0-10 Pain Visual Numeric Scale participants will rate their pain in the past 2 weeks on an 11-item scale ranging from 0 (no pain) to 10 (severe pain).
|
Change between baseline and 52 weeks
|
|
Defense and Veterans Pain Rating Scale
Tijdsspanne: Change between baseline and 52 weeks
|
Using the Defense and Veterans Pain Rating Scale will rate their pain in the past 2 weeks on an 11-item scale ranging from 0 (no pain) to 10 (severe pain).
|
Change between baseline and 52 weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Pain interference with sleep
Tijdsspanne: Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
Defense and Veterans Pain Rating Scale Supplemental Question (revised from 24 hours to past 2 weeks)
|
Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
|
Pain frequency
Tijdsspanne: Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
2016 NHIS (past 3 months)
|
Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
|
Perceived disability
Tijdsspanne: Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
Pain Disability Index
|
Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
|
Pain avoidance
Tijdsspanne: Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
Tampa Scale of Kinesiophobia.
A total score is calculated that ranges from 17 (low degree of kinesiophobia) to 68 (a high degree of kinesiophobia)
|
Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
|
Opioid misuse
Tijdsspanne: Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
Screener and Opioid Assessment for Patients with Pain (SOAPP) v1.0-SF
|
Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
|
Medication Usage
Tijdsspanne: Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
Morphine milligram equivalents (MME) per day of current prescription or over-the-counter medications for pain, depression, anxiety, mood, or sleep (also usage of stimulants and muscle relaxers)
|
Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
|
Mood
Tijdsspanne: Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
Stanford Personal Health Questionnaire-Depression (PHQ-8)
|
Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
|
Anxiety
Tijdsspanne: Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
Generalized Anxiety Disorder-7 (GAD-7)
|
Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
|
Catastrophizing
Tijdsspanne: Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
Pain Catastrophizing Scale.
The total score ranges from 0 (low catastrophizing) to 52 (high catastrophizing).
There are 3 subscales (rumination, magnification, and helplessness)
|
Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
|
Mindfulness
Tijdsspanne: Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
5 Facet Mindfulness Questionnaire Short Form
|
Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
|
Pain Self-Efficacy
Tijdsspanne: Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
Pain Self-Efficacy Scale.
The total score ranges from 0 (low self-efficacy) to 60 (high self-efficacy)
|
Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
|
Coping
Tijdsspanne: Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
Coping Strategies Questionnaire-Revised
|
Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
|
Activation
Tijdsspanne: Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
Patient Activation Measure
|
Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
|
General Health Status
Tijdsspanne: Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
2016 BRFSS question
|
Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
|
Vitality
Tijdsspanne: Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
SF-36 v1
|
Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
|
Minutes of Physical Activity
Tijdsspanne: Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
2016 NHIS questions
|
Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
|
Healthcare Utilization
Tijdsspanne: Monthly for up to 12 months
|
Emergency room visits and doctor/clinic visits
|
Monthly for up to 12 months
|
|
Work
Tijdsspanne: Monthly for up to 12 months
|
Number of days missed work and number of days in bed more than half of the day
|
Monthly for up to 12 months
|
|
Gait speed
Tijdsspanne: Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
5- or 10-meter gait speed test
|
Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
Medewerkers en onderzoekers
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 3U48DP005004-04S1 (Subsidie/contract van de Amerikaanse NIH)
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .